Case-control Study of the Effectiveness of Vaccination With Pentavalent Rotavirus Vaccine in Nicaragua

201149 citationsJournal Article

Authors

T. Christopher Mast · Merck & Co., Inc., Rahway, NJ, USA (United States)

Shazia Khawaja · Merck & Co., Inc., Rahway, NJ, USA (United States)

Félix Espinoza · Universidad Nacional Autónoma de Nicaragua-León

Margarita Paniagua · Universidad Nacional Autónoma de Nicaragua-León

Leonel Palacio Del Carmen · Hospital Infantil Manuel de Jesús Rivera

Anna Cardellino · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

The Merck-Nicaragua Rotavirus Vaccine Partnership promoted rapid and widespread uptake of a novel vaccine in a developing country. Vaccine effectiveness was greatest for children younger than 12 months of age who were at the highest risk for severe rotavirus disease.

Topics & Keywords

Viral gastroenteritis research and epidemiology Hepatitis Viruses Studies and Epidemiology Viral Infections and Immunology Research

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: The Pediatric Infectious Disease Journal

Volume 30, Issue 11, pp. e209-e215

DOI: 10.1097/inf.0b013e31822a8527

Field-Weighted Citation Impact: 3.29